A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Complement C1 inhibitor protein (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors CSL Behring
- 26 Jul 2018 Planned End Date changed from 16 Oct 2023 to 15 Jan 2026.
- 26 Jul 2018 Planned primary completion date changed from 16 Jul 2020 to 15 Jan 2026.
- 07 Sep 2017 Planned End Date changed from 1 Jul 2020 to 16 Oct 2023.